Orrick Advises K Health on $132 Million Series E Round
| January.20.2021
Congratulations to our healthcare technology client K Health on its $132 million Series E financing round.
Helping life
sciences
companies
innovate
and grow
Life Sciences Sector
Our Life Sciences practice is built around our core commitment to support the development of technology that improves lives.
Client Results
Orrick Advises Aledade on $100 Million Series D
| January.19.2021
Orrick congratulates healthcare technology client Aledade on its $100 million Series D financing round.
Orrick Advises Swoop on Acquisition by W2O
| January.08.2021
Orrick has advised AI solutions provider Swoop on its acquisition by global health innovation company W2O.
Orrick Advises VNV Global on Its Investment in Babylon’s $100 Million Financing
| December.17.2020
We have advised VNV Global on its investment in digital healthcare service provider Babylon’s $100 million financing round.
Orrick Advises Clover Health on $3.7 Billion SPAC Merger
| October.06.2020
Orrick is advising San Francisco-based healthcare technology company Clover Health on its definitive agreement to become publicly traded via a SPAC ...
Orrick Advises Warburg Pincus' Qualifacts on Merger with Credible Behavioral Health
| August.25.2020
Orrick has advised global private equity firm Warburg Pincus and its portfolio company, Qualifacts, on its merger with Credible Behavioral Health, a ...
Orrick Advises Twist Bioscience on $107.4 Million Follow-On Offering
| June.08.2020
Orrick has advised San Francisco-based synthetic biology company Twist Bioscience (NASDAQ: TWST) on its $107.4 million follow-on offering.
Orrick Advises Tiziana on U.S. Follow-On Offering
| March.17.2020
Orrick’s Ed Lukins has advised biotech company Tiziana Life Sciences on its U.S. follow-on offering of 3,333,333 of American Depositary Shares (ADS) ...
Orrick Advises Oisín Biotechnologies on Financing
| March.02.2020
Orrick has advised Seattle-based biotechnology company Oisín Biotechnologies on its $3 million pre-seed SAFE funding round.
Orrick Advises Cortexyme on $125 Million Private Placement
| February.11.2020
Orrick has advised San Francisco-based biopharmaceutical company Cortexyme (Nasdaq: CRTX) on its $125 million private placement of common stock.
Insights
Using M&A Insurance on Tech Deals: Issue 3: Fintech, edtech and healthtech/medtech
by Peter M. Lamb, David M. Ruff, Hari Raman, Daniel Lopez and Zac Padgett | January.21.2021
We dig deeper into key underwriting topics for fintech, edtech and healthtech/medtech deals.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q3 2020
| October.22.2020
Venture Surges and the Rise of SPACs
In this edition, the traditional update on broader venture market financing data is included.
In this edition, the traditional update on broader venture market financing data is included.
Investments in Germany under COVID 19 – Turning a Crisis into Opportunities
by Dr. Oliver Duys LL.M. (UNSW Sydney), Abhijit Narayan and Hayat Makhloufi | August.17.2020
This article provides an overview about the recent investment trends in Germany in view of the COVID-19 pandemic.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q2 2020
by Stephen Thau, Scott M. Iyama, Gregg Griner, Albert Vanderlaan, Blake Ilstrup and Neel Lilani | August.10.2020
Companies & Investors Navigate the Pandemic Era
In this new series, our expert lawyers explore trends in venture investing across the life sciences ...
China Proposes to Tighten Biosecurity Law and its Potential Impact on Foreign Pharmaceutical and Biotech Companies Operating in China
by Betty L. Louie, Yufeng (Ethan) Ma and Martha Wang | July.10.2020
On April 26, 2020, the Standing Committee of the National People's Congress, China’s top legislature, passed the second draft of the country’s ...
Board Oversight of Clinical Trials During the Pendency of the COVID-19 Pandemic
by Albert Vanderlaan and Stephen Thau | June.19.2020
COVID-19 has had far-reaching social, economic and regulatory impacts. Nearly all companies (private and public, large and small) have had reason to ...
Direct Listings May Pose Challenges for Cash Intensive Life Sciences Companies
by Albert Vanderlaan | May.14.2020
Are direct listings a viable potential alternative for all companies seeking to go public? The answer may likely be no.
Managing and Maintaining Clinical Trial Disclosure for Publicly Traded Life Sciences Companies
by Albert Vanderlaan | May.21.2020
The following discussion is intended to help guide companies in making clinical trial-related disclosures.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2020
by Stephen Thau, Scott M. Iyama, Gregg Griner, Albert Vanderlaan and Blake Ilstrup | May.11.2020
The Market Meets COVID-19
In this new series, our expert lawyers explore trends in venture investing across the life sciences sector.
In this new series, our expert lawyers explore trends in venture investing across the life sciences sector.
Dusting the Regulatory Framework – French Competition Authority Seeks to Liberalize Distribution of Drugs and Private Medical Biology
by Marie-Laure Combet and Elise Durand | April.26.2019
On April 4, 2019, just three months after the publication of the European Commission (EC) report on “Competition enforcement in the pharmaceutical ...
Profiles in Innovation: Twist Bioscience’s Co-Founder Navigates Company from Start-up to Public Company
| February.21.2019
Emily Leproust discusses her inspiration and journey building a public company in the fast growing synthetic DNA market with commentary from Orrick ...
Scope of Estoppel Post-IPR Proceedings Becoming Clearer
by K. Patrick Herman | March.27.2017
This estoppel provision has been the subject of a number of Federal Circuit and district court decisions.
HALLOWEEN TREAT: Judge’s October 31 Order Adds $21 Million to Jury’s $70 Million Award for Trade Secret Theft
by Mona S. Amer | November.22.2016
On October 31st of this year, a district judge in Massachusetts granted a motion for enhanced damages in a theft of trade secrets case, adding an ...
Confidential Settlement Amounts Are Not Necessarily Confidential
| June.10.2016
Courts in the Northern District of California, which have been handling price-fixing class actions in the electronics industry for more than a ...
Supreme Courts Request for Views of the United States on Cert Petition in Lamictal ReversePayment C
by Robert Reznick | June.09.2016
On Monday, June 7, the Supreme Court requested the views of the Solicitor General in connection with a petition for certiorari filed by the U.S. ...
News
Orrick Adds Life Sciences Licensing Advisor Shana Solomon
| September.09.2020
Orrick announced today that Shana Solomon, a seasoned advisor to companies in the life science, biotechnology and pharmaceutical industries, has ...
Orrick Adds Corporate Advisor Ed Lukins in London
| September.18.2019
Orrick announced today that leading corporate advisor Ed Lukins has joined the firm as a partner based in London. He joins from Cooley, where he ...
Orrick Recruits Life Sciences & Tech Advisor Gregg Griner to Lead Boston Corporate Practice
| September.04.2019
Continuing the growth of Orrick’s Boston office, the firm announced today that Life Sciences and Technology advisor Gregg Griner has joined the firm ...
Antitrust Watch Blog
In-depth analysis and commentary on major developments in global antitrust and competition law
"Enjoys a fine reputation for its work in the technology and life sciences arenas.”
2016 Chambers USA - Capital Markets (California)
The World in U.S. Courts
A quarterly review of the most important decisions applying U.S. law to global business and cross-border activities.
Some of the recognition we have received
IP Group of the Year
Law360, 4 times
Tech Group of the Year
Law360, 2018 and 3 times
Employment Group of the Year
Law360, 2018 and 3 times
Recommended
Global Competition Review 100, 2019
IP Litigation Department of the Year
The American Lawyer, 2016
Top 5 Litigation Powerhouse
Law360, 2016
Litigation Power Rankings – Top 10
The American Lawyer, 2016
Appellate Hot List
National Law Journal, 2018 and 7 times
Litigation Department of the Year
The Recorder, 2016 and 2 times
Labor & Employment Defense Firm of the Year
The Recorder, 2017 and 4 times
International IP Firm of the Year
China Law & Practice, 2015
Tier 1 for China Patent Work
Asian Legal Business, 2013-2018
China Foreign Law Firm of the Year
Managing IP, 2016